Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Amended and Restated License...License Agreement • July 26th, 2022 • Avista Public Acquisition Corp. II • Services-commercial physical & biological research • New York
lcagen, LLC (formerly known as Adjacent Acquisition Co., LLC; as assignee from lcagen, lnc., the party to the original License Agreement)
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ANTIBODY LICENSE AGREEMENTAntibody License Agreement • July 26th, 2022 • Avista Public Acquisition Corp. II • Services-commercial physical & biological research • New York
This Antibody License Agreement (“Agreement”) is entered into effective December 20, 2012 (“Effective Date”) by Open Monoclonal Technologies, Inc. (“OMT”), a Delaware corporation having its principal place of business at 2747 Ross Road, Suite A, Palo Alto, CA 94303 and CNA Development LLC (“Licensee”), a Delaware limited liability company, having its principal place of business at [***].
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. RESEARCH, DEVELOPMENT AND...Development and Commercialization Agreement • July 26th, 2022 • Avista Public Acquisition Corp. II • Services-commercial physical & biological research • Delaware
This Agreement (this “Agreement”) is made on this 1st day of May, 2018 and shall be effective on the Effective Date by and between Icagen, Inc. (“Icagen”), a corporation having a principal place of business at [***] acting on behalf of itself and Affiliates, and Cystic Fibrosis Foundation (“CFF”), a nonprofit corporation with its principal offices at [***], and shall become effective on the Effective Date. Icagen and CFF are each referred to herein individually as a “Party” and collectively as the “Parties”.
